Abstract: The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMTS inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMTS associated disorders are also described.

Abstract: The present disclosure describes novel IDO inhibitors and methods for preparing them.

Abstract: This invention is a fully functional workflow platform or middleware on a mobile device that is able to create, modify and execute its own workflows and synchronize with external services on the mobile device or on a remote back-end such as a server using asynchronous and/or synchronous communications. This invention also includes a back-end computing platform that integrates with the mobile device and with a blockchain.

Abstract: A biological sample processing system (1) includes a liquid droplet manipulation instrument (20) with an electrode array (21) for inducing a movement of a liquid droplet (19) by electrowetting; a substrate (22); and a control unit (23). An electrode selector (34) of the control unit (23) is configured to individually select and provide each electrode (35) of the electrode array (21) with a voltage. The control unit (23) includes a central processing unit (36) for individually selecting at least one electrode (35) and for providing the selected electrode(s) (35) with an individual voltage pulse. The biological sample processing system (1) also includes a cartridge (40) with a container (2).

Abstract: A biological sample processing system (1) includes a liquid droplet manipulation instrument (20) with an electrode array (21) for inducing a movement of a liquid droplet (19) by electrowetting; a substrate (22); and a control unit (23). An electrode selector (34) of the control unit (23) is configured to individually select and provide each electrode (35) of the electrode array (21) with a voltage. The control unit (23) includes a central processing unit (36) for individually selecting at least one electrode (35) and for providing the selected electrode(s) (35) with an individual voltage pulse. The biological sample processing system (1) also includes a cartridge (40) with a container (2).

Abstract: Liquid droplet manipulation instrument has electrode array for inducing movement of a droplet by electrowetting, substrate supporting the array and control with electrode selector connected to a voltage control. The selector selects each electrode and provides each with a controlled voltage. The control includes central processing unit for providing the selected electrode with an individual voltage pulse which is a drive voltage or a ground voltage or a stop voltage. The control defines a path for movement of a liquid portion of a larger volume that covers more than one electrode by the simultaneous selection of a group of two or more subsequent drive electrodes and to provide each selected drive electrode with a drive voltage pulse along the path. The control simultaneously provides a group of two or more electrodes adjacent to or identical with the pulsed drive electrodes, with a ground or stop voltage pulse.

Abstract: The present invention is directed to conjugated compounds comprising a folate, or an analog or derivative thereof, and an aziridinyl epothilone analog, as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof, useful in the treatment of cancer or other folate-receptor associated conditions.

Abstract: The present invention is directed to aziridinyl epothilone compounds as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof having the following Formula: wherein K is —O—, —S—, or —NR7—; A is —(CR8R9)—(CH2)m-Z- wherein Z is —(CHR10)—, —C(?O)—, —C(?O)—C(?O)—, —OC(?O)—, —N(R11)C(?O)—, —SO2—, or —N(R11)SO2—; B1 is hydroxyl or cyano and R1 is hydrogen or B1 and R1 are taken together to form a double bond; R2, R3, and R5 are, independently, hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; or R2 and R3 may be taken together with the carbon to which they are attached to form an optionally substituted cycloalkyl; R4 is hydrogen, alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, or substituted aryl; R6 is hydrogen, alkyl or substituted alkyl; R7, R8, R9, R10, R11 and R12 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or sub

Abstract: A method of two-way communication between a web browser and a mobile telecommunication device including the steps of; accessing a web-site via a computer, sending a message to a mobile telecommunication device from the web-site, and at a message server capturing information uniquely identifying the computer, assigning an identification number to the information uniquely identifying the computer, storing the identification number and information uniquely identifying the computer in a database, and sending the message to the mobile telecommunication device with the identification number.

Abstract: The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

Abstract: The present disclosure is directed to a method of treating bone metastasis, hypercalcemia, and/or bone resorption comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or pharmaceutically acceptable salt, hydrate or solvate thereof.

Abstract: An inkjet printhead chip includes a substrate, transistors, isolation structures, a dielectric layer, a resistive layer and conductive sections. Each transistor includes a gate, a source, a drain and a gate oxide disposed between the gate and the substrate. The isolation structures are on the substrate surface and isolate the transistors. The dielectric layer covers the transistors and the isolation structures, and has openings exposed the source and the drain. Several heating regions are in the resistive layer that is on the dielectric layer. In the conductive sections, the first conductive section is on the resistive layer and exposes the heating regions for forming several heating devices. Each heating device has resistance less than 95 ohm and power density less than 2 GW/m2; the second conductive section and the third conductive section are electrically coupled to the drain and the source through the openings of the dielectric layer respectively.

Abstract: The invention relates to a combination of BCR-ABL inhibitor, exemplified by ?N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and/or other BCR/ABL inhibitors, and a stem cell selective cytotoxic, exemplified by (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile, hydrochloride salt, and or other stem cell cytotoxic agents, pharmaceutical compositions of the combination and to methods of using the pharmaceutical compositions in the treatment of oncological disorders.

Abstract: Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided.

Abstract: A combination and methods are disclosed which are useful for the treatment of cancer and/or leukemia.

Abstract: Novel compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as oncologic and immunologic disorders.

Abstract: The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

Abstract: The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase.

Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.

Abstract: A bone graft composite comprising a bisphosphonate is provided which is suitable for treating bone destruction. The bisphosphonate provides bone graft protection.